493 related articles for article (PubMed ID: 16585503)
1. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
Bielekova B; Catalfamo M; Reichert-Scrivner S; Packer A; Cerna M; Waldmann TA; McFarland H; Henkart PA; Martin R
Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5941-6. PubMed ID: 16585503
[TBL] [Abstract][Full Text] [Related]
2. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells.
Martin JF; Perry JS; Jakhete NR; Wang X; Bielekova B
J Immunol; 2010 Jul; 185(2):1311-20. PubMed ID: 20543101
[TBL] [Abstract][Full Text] [Related]
3. Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis.
Jiang W; Chai NR; Maric D; Bielekova B
J Immunol; 2011 Jul; 187(2):781-90. PubMed ID: 21666061
[TBL] [Abstract][Full Text] [Related]
4. Daclizumab Therapy for Multiple Sclerosis.
Bielekova B
Cold Spring Harb Perspect Med; 2019 May; 9(5):. PubMed ID: 29661806
[TBL] [Abstract][Full Text] [Related]
5. Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis.
Sheridan JP; Zhang Y; Riester K; Tang MT; Efros L; Shi J; Harris J; Vexler V; Elkins JS
Mult Scler; 2011 Dec; 17(12):1441-8. PubMed ID: 21807759
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the Impact of Daclizumab Beta on Circulating Natural Killer Cells by Mass Cytometry.
Ranganath T; Simpson LJ; Ferreira AM; Seiler C; Vendrame E; Zhao N; Fontenot JD; Holmes S; Blish CA
Front Immunol; 2020; 11():714. PubMed ID: 32391016
[TBL] [Abstract][Full Text] [Related]
7. Population PK-PD analyses of CD25 occupancy, CD56
Diao L; Hang Y; Othman AA; Mehta D; Amaravadi L; Nestorov I; Tran JQ
Br J Clin Pharmacol; 2016 Nov; 82(5):1333-1342. PubMed ID: 27333593
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis.
Perry JS; Han S; Xu Q; Herman ML; Kennedy LB; Csako G; Bielekova B
Sci Transl Med; 2012 Aug; 4(145):145ra106. PubMed ID: 22855463
[TBL] [Abstract][Full Text] [Related]
9. Daclizumab therapy for multiple sclerosis.
Bielekova B
Neurotherapeutics; 2013 Jan; 10(1):55-67. PubMed ID: 23055048
[TBL] [Abstract][Full Text] [Related]
10. Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis.
Li Z; Lim WK; Mahesh SP; Liu B; Nussenblatt RB
J Immunol; 2005 May; 174(9):5187-91. PubMed ID: 15843513
[TBL] [Abstract][Full Text] [Related]
11. Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.
Zhang Y; McClellan M; Efros L; Shi D; Bielekova B; Tang MT; Vexler V; Sheridan JP
Mult Scler; 2014 Feb; 20(2):156-64. PubMed ID: 23846354
[TBL] [Abstract][Full Text] [Related]
12. Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.
Baldassari LE; Rose JW
Neurotherapeutics; 2017 Oct; 14(4):842-858. PubMed ID: 28707278
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation.
Hao J; Campagnolo D; Liu R; Piao W; Shi S; Hu B; Xiang R; Zhou Q; Vollmer T; Van Kaer L; La Cava A; Shi FD
Ann Neurol; 2011 Apr; 69(4):721-34. PubMed ID: 21425186
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis.
Laroni A; Armentani E; Kerlero de Rosbo N; Ivaldi F; Marcenaro E; Sivori S; Gandhi R; Weiner HL; Moretta A; Mancardi GL; Uccelli A
J Autoimmun; 2016 Aug; 72():8-18. PubMed ID: 27157273
[TBL] [Abstract][Full Text] [Related]
15. Daclizumab (anti-CD25) in multiple sclerosis.
Pfender N; Martin R
Exp Neurol; 2014 Dec; 262 Pt A():44-51. PubMed ID: 24768797
[TBL] [Abstract][Full Text] [Related]
16. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
Bielekova B; Howard T; Packer AN; Richert N; Blevins G; Ohayon J; Waldmann TA; McFarland HF; Martin R
Arch Neurol; 2009 Apr; 66(4):483-9. PubMed ID: 19364933
[TBL] [Abstract][Full Text] [Related]
17. Circulating innate lymphoid cells are unchanged in response to DAC HYP therapy.
Gillard GO; Saenz SA; Huss DJ; Fontenot JD
J Neuroimmunol; 2016 May; 294():41-5. PubMed ID: 27138097
[TBL] [Abstract][Full Text] [Related]
18. Daclizumab in multiple sclerosis.
Perez-Miralles FC
Rev Neurol; 2018 Apr; 66(8):271-282. PubMed ID: 29645071
[TBL] [Abstract][Full Text] [Related]
19. Anticipated benefits and surprising effects of daclizumab in multiple sclerosis.
Stüve O; Greenberg BM
Lancet Neurol; 2010 Apr; 9(4):337-8. PubMed ID: 20163991
[No Abstract] [Full Text] [Related]
20. Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation.
Gross CC; Schulte-Mecklenbeck A; Rünzi A; Kuhlmann T; Posevitz-Fejfár A; Schwab N; Schneider-Hohendorf T; Herich S; Held K; Konjević M; Hartwig M; Dornmair K; Hohlfeld R; Ziemssen T; Klotz L; Meuth SG; Wiendl H
Proc Natl Acad Sci U S A; 2016 May; 113(21):E2973-82. PubMed ID: 27162345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
